Long-term health care resource and cost savings with allergy immunotherapy: REACT study results.

Autor:	Fritzsching B; Paediatric Pulmonology and Allergy, Children's Doctor Service, Heidelberg, Germany., Porsbjerg C; Department of Respiratory Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark., Contoli M; Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy., Buchs S; Global Market Access, ALK-Abelló, Hørsholm, Denmark., Larsen JR; Global Medical Affairs, ALK-Abelló, Hørsholm, Denmark., Freemantle N; Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	The journal of allergy and clinical immunology. Global [J Allergy Clin Immunol Glob] 2023 Nov 23; Vol. 3 (1), pp. 100197. Date of Electronic Publication: 2023 Nov 23 (Print Publication: 2024).
DOI:	10.1016/j.jacig.2023.100197
Abstrakt:	Background: Allergy immunotherapy (AIT) can be administered as subcutaneous immunotherapy (SCIT) injections in the clinic or as sublingual immunotherapy (SLIT) tablets at home after initiation under medical supervision. To achieve long-term, sustained effects, a 3-year treatment duration is recommended. Objective: Our aim was to assess the association of AIT (SCIT and SLIT tablets) with long-term health care resource use (HRU) and costs in subjects with allergic rhinitis. Methods: REACT was a retrospective propensity score-matched cohort study using claims data from a German health insurance database (2007-2017), with up to 9 years of follow-up after AIT initiation. HRU and costs were evaluated for hospitalizations, ambulatory care visits, and prescriptions, in subjects who received AIT versus in matched controls with allergic rhinitis who had not received AIT, as well as for SCIT and SLIT tablets. Results: Across all 9 years, the subjects who received AIT had a significantly lower incidence of hospitalization than the controls did. Generally, proportions of subjects with ambulatory care visits and hospitalizations were lower, and length of hospitalization was shorter, for those receiving SLIT tablets than those who received SCIT. Total costs were significantly higher with AIT versus for the controls during the treatment period (years 1 to 3), driven by prescriptions and ambulatory care visits, but they were lower in years 4 to 9. During years 1 to 3, prescription costs were generally higher for SLIT tablets than for SCIT, whereas ambulatory care costs were numerically lower. In most years, hospitalization costs were numerically lower for SLIT tablets than for SCIT. Conclusion: Initial higher HRU and costs of AIT during the expected treatment period are offset in the long term. At-home administration of SLIT tablets may further reduce ambulatory care costs. Competing Interests: Supported by ALK-Abelló. Disclosure of potential conflict of interest: This study was conducted and funded by ALK-Abelló. B. Fritzsching reports personal fees from ALK-Abelló and speaker honoraria from 10.13039/100004336Novartis and 10.13039/100009947Merck Sharp & Dohme. C. Porsbjerg reports grants from ALK-Abelló, as well as grants and personal fees from 10.13039/100004325AstraZeneca, 10.13039/100004330GlaxoSmithKline, Novartis, Chiesi, Sanofi, and TEVA. M. Contoli reports personal fees from ALK-Abelló; personal fees and nonfinancial support from 10.13039/100004325AstraZeneca, 10.13039/100008349Boehringer Ingelheim, Novartis, and Zambon; grants, personal fees, and nonfinancial support from Chiesi and GlaxoSmithKline; and grants from the University of Ferrara, Italy. S. Buchs and J. R. Larsen are employees of ALK-Abelló. N. Freemantle reports personal fees from AstraZeneca, Ipsen, Sanofi Aventis, Grifols, Novartis, Aimmune, Vertex, MSD, and Allergan. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu